Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02). (6th November 2014) - Patel, Sapna; Milhem, Mohammed; Hallmeyer, Sigrun; Daniels, Gregory; Cranmer, Lee; Taback, Bret; Flaherty, Lawrence; Aung, Sandra; Lowder, James; Sharfman, William